Your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Publications

Relevant MF Publications

All Publications

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes

Relevant MF Publications

Cancer 2022

Mascarenhas, et al.

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation

Relevant MF Publications

Annals of Hematology 2018

Kuykendall, et al.

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Relevant MF Publications

Newberry, et al.

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

Relevant MF Publications

Blood Advances 2017

Spiegel, et al.

Characterization of Disease, Treatment Patterns, and Outcomes of Patients With Myelofibrosis: Analysis of Two United States Commercial Claims Databases

Relevant MF Publications

Mehra M, et al.

How I treat myelofibrosis

Relevant MF Publications

Cervantes F, et al.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

Relevant MF Publications

Tefferi A, et al.

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

Relevant MF Publications

Journal of Clinical Oncology 2011

Gangat N, et al.

[facetwp facet="publication_load_more"]